CL2023003455A1 - Engineered polypeptides - Google Patents
Engineered polypeptidesInfo
- Publication number
- CL2023003455A1 CL2023003455A1 CL2023003455A CL2023003455A CL2023003455A1 CL 2023003455 A1 CL2023003455 A1 CL 2023003455A1 CL 2023003455 A CL2023003455 A CL 2023003455A CL 2023003455 A CL2023003455 A CL 2023003455A CL 2023003455 A1 CL2023003455 A1 CL 2023003455A1
- Authority
- CL
- Chile
- Prior art keywords
- polypeptides
- engineered polypeptides
- variants
- polypeptide
- igg
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/116—Togaviridae (F); Matonaviridae (F); Flaviviridae (F)
- C07K16/118—Hepatitis C virus; GB virus C [GBV-C]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192549P | 2021-05-24 | 2021-05-24 | |
| US202163265032P | 2021-12-06 | 2021-12-06 | |
| US202263266453P | 2022-01-05 | 2022-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003455A1 true CL2023003455A1 (es) | 2024-07-19 |
Family
ID=82156443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003455A CL2023003455A1 (es) | 2021-05-24 | 2023-11-21 | Engineered polypeptides |
Country Status (13)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3183367A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| CA3183373A1 (en) | 2020-07-06 | 2022-01-13 | Gevorg GRIGORYAN | Antigen binding molecules targeting sars-cov-2 |
| KR20230058434A (ko) | 2020-08-26 | 2023-05-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | SARS-CoV-2를 표적으로 하는 항원 결합 분자 |
| WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
| WO2023245078A1 (en) | 2022-06-15 | 2023-12-21 | Humabs Biomed Sa | Anti-parvovirus antibodies and uses thereof |
| WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
| JP2025526405A (ja) | 2022-07-27 | 2025-08-13 | ヒューマブス・バイオメッド・ソシエテ・アノニム | Rsv及びmpvパラミクソウイルスに対する広域中和抗体 |
| WO2024182781A1 (en) | 2023-03-02 | 2024-09-06 | Vir Biotechnology, Inc. | Coronavirus compositions and uses thereof |
| TW202446788A (zh) | 2023-04-10 | 2024-12-01 | 美商維爾生物科技公司 | 結合多種薩貝冠狀病毒之抗體 |
| WO2025010424A1 (en) | 2023-07-06 | 2025-01-09 | Vir Biotechnology, Inc. | Antibodies against staphylococcus antigens and methods of using the same |
| EP4743488A1 (en) | 2023-07-13 | 2026-05-20 | VIR Biotechnology, Inc. | Antibodies widely neutralizing against paramyxoviruses RSV and MPV |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| WO2005028515A1 (ja) | 2003-09-24 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| WO2010033279A2 (en) * | 2008-06-04 | 2010-03-25 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| CN103261222B (zh) | 2010-09-10 | 2017-07-28 | 医疗免疫有限公司 | 抗体衍生物 |
| US9663581B2 (en) | 2012-04-25 | 2017-05-30 | Momenta Pharmaceuticals, Inc. | Modified glycoproteins |
| AU2014374055B2 (en) | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| US20160257761A1 (en) * | 2015-03-06 | 2016-09-08 | Macrogenics, Inc. | HER2/neu-Specific Antibodies and Methods of Using Same |
| US11267899B2 (en) | 2015-05-13 | 2022-03-08 | Zumutor Biologics Inc. | Afucosylated protein, cell expressing said protein and associated methods |
| US20200157192A1 (en) * | 2017-05-10 | 2020-05-21 | Albajuna Therapeutics, S.L. | Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| CN117843810A (zh) | 2017-09-22 | 2024-04-09 | 上海药明生物技术有限公司 | 新型双特异性多肽复合物 |
| JP7351845B2 (ja) * | 2018-03-23 | 2023-09-27 | ブリストル-マイヤーズ スクイブ カンパニー | Micaおよび/またはmicbに対する抗体ならびにそれらの使用 |
| US20220298230A1 (en) * | 2019-06-11 | 2022-09-22 | The Rockefeller University | Antibodies and methods for treatment of viral infections |
-
2022
- 2022-05-23 KR KR1020237044483A patent/KR20240035758A/ko active Pending
- 2022-05-23 TW TW111119113A patent/TW202306978A/zh unknown
- 2022-05-23 BR BR112023024494A patent/BR112023024494A2/pt unknown
- 2022-05-23 CA CA3218489A patent/CA3218489A1/en active Pending
- 2022-05-23 JP JP2023572165A patent/JP2024521131A/ja active Pending
- 2022-05-23 MX MX2023013859A patent/MX2023013859A/es unknown
- 2022-05-23 AU AU2022280767A patent/AU2022280767A1/en active Pending
- 2022-05-23 IL IL308509A patent/IL308509A/en unknown
- 2022-05-23 WO PCT/US2022/030556 patent/WO2022251119A2/en not_active Ceased
- 2022-05-23 US US18/563,674 patent/US20250296986A1/en active Pending
- 2022-05-23 EP EP22732744.2A patent/EP4347642A2/en active Pending
-
2023
- 2023-11-21 CL CL2023003455A patent/CL2023003455A1/es unknown
- 2023-12-19 CO CONC2023/0017754A patent/CO2023017754A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022251119A2 (en) | 2022-12-01 |
| AU2022280767A1 (en) | 2024-01-18 |
| EP4347642A2 (en) | 2024-04-10 |
| WO2022251119A9 (en) | 2023-10-05 |
| MX2023013859A (es) | 2024-02-15 |
| IL308509A (en) | 2024-01-01 |
| TW202306978A (zh) | 2023-02-16 |
| CO2023017754A2 (es) | 2024-05-10 |
| CA3218489A1 (en) | 2022-12-01 |
| WO2022251119A3 (en) | 2023-01-12 |
| US20250296986A1 (en) | 2025-09-25 |
| JP2024521131A (ja) | 2024-05-28 |
| BR112023024494A2 (pt) | 2024-02-06 |
| KR20240035758A (ko) | 2024-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023017754A2 (es) | Polipéptidos modificados | |
| CU20200090A7 (es) | Anticuerpos frente a entpd2 y terapias de combinación | |
| CL2020000039A1 (es) | Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes. (divisional solicitud 201700647) | |
| MX2022006078A (es) | Terapias de combinacion para el tratamiento del cancer. | |
| SA521421825B1 (ar) | (glp1) البروتينات الاندماجية المتمثلة في الببتيد 1 الشبيه بالجلوكاجون (gdf15) وعامل تمايز النمو 15 واستخدامه | |
| CO2018005436A2 (es) | Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica | |
| MX2016008782A (es) | Variantes de region fc con union mejorada de la proteina a. | |
| DOP2017000047A (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
| UY37576A (es) | Anticuerpos dirigidos a hueso | |
| CL2015002720A1 (es) | Composición y kit farmacéutico de un polipéptido quimérico del factor viii y fc. | |
| ECSP22049014A (es) | Variantes de progranulina | |
| WO2006036550A3 (en) | Listeria-based and llo-based vaccines | |
| MX2024004294A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
| MX2017004664A (es) | Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. | |
| CL2008000104A1 (es) | Proteina de fusion que comprende un antigeno asociado a tumor (prame) o un fragmento inmunogenico de el y un derivado de proteina d; secuencia nucleotidica que codifica dicha proteina; vector y celula huesped que comprenden la proteina; vacuna que co | |
| BR112023017749A2 (pt) | Composições incluindo adjuvantes sbi e métodos de uso das mesmas | |
| PE20230381A1 (es) | Proteina de union a rgma | |
| MX387560B (es) | Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina. | |
| MX2021015763A (es) | Polipeptidos. | |
| GEAP202515689A (en) | Treatment of medication overuse headache using anti-cgrp or anti-cgrp-r antibodies | |
| MX2020011529A (es) | Un metodo para optimizar la expresion de anticuerpos. | |
| MX2020010740A (es) | Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso. | |
| EP3784692C0 (en) | CYCLIC TYROSINE-TYROSINE PEPTIDE CONJUGATES COUPLED TO A GLUCAGON-RELATED PEPTIDE 1 (GLP-1) FUSION PEPTIDE AND USES THEREOF | |
| CO2024001388A2 (es) | Anticuerpos y fragmentos de unión al antígeno anti-glicoproteína de la espícula de sars-cov-2 | |
| AR118443A1 (es) | Proteínas de fusión, bacterias recombinantes y fragmentos de exosporas para control de plagas y salud de las plantas |